Orasure Technologies Inc. (OSUR)
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.
OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.
OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Carrie Eglinton Manner - President, CEO & Director Jason Michael Plagman - Vice President of Investor Relations Kenneth J. McGrath - Chief Financial Officer Conference Call Participants Noah Lewis - Raymond James & Associates, Inc., Research Division Operator Good day, and thank you for standing by.
OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.07 per share a year ago.
OraSure Technologies: An Asymmetric Bet
OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target.
Orasure Technologies: Multiple Shots To Deliver Value
OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth.
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call.
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago.
OraSure Technologies: Historically Cheap
OraSure Technologies shares have dipped below $3 since my last writing, making shares even cheaper. Recent developments at the company include the acquisition of Sherlock Biosciences and the announcement of a $40 million share repurchase program. OSUR is enhancing business efficiency through cost cuts and aims to expand gross margins to 50% by year-end 2025, mitigating acquisition-related cash burn.
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Inc. 2024 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
